Published in Arch Intern Med on May 12, 2003
Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV | NCT00080119
PROvide MIner-friendly SErvices for Integrated TB/HIV Care in Lesotho Study (PROMISE) | NCT03537872
Prevalence of Latent Tuberculosis in High Risk Young Children | NCT03910946
Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis (2008) 5.94
Host range and emerging and reemerging pathogens. Emerg Infect Dis (2005) 5.90
Cell-mediated immune responses in tuberculosis. Annu Rev Immunol (2009) 5.90
Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med (2007) 5.63
Ipr1 gene mediates innate immunity to tuberculosis. Nature (2005) 4.53
Confronting the scientific obstacles to global control of tuberculosis. J Clin Invest (2008) 4.41
Monitoring global health: time for new solutions. BMJ (2004) 4.39
Active case finding of tuberculosis: historical perspective and future prospects. Int J Tuberc Lung Dis (2005) 4.36
Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet (2014) 4.25
Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence. BMC Public Health (2007) 4.13
A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med (2011) 4.09
The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS (2007) 4.09
Paediatric tuberculosis. Lancet Infect Dis (2008) 3.97
The enduring hypoxic response of Mycobacterium tuberculosis. PLoS One (2008) 3.87
Molecular epidemiology of tuberculosis: current insights. Clin Microbiol Rev (2006) 3.79
Natural ventilation for the prevention of airborne contagion. PLoS Med (2007) 3.73
Serial testing of health care workers for tuberculosis using interferon-gamma assay. Am J Respir Crit Care Med (2006) 3.70
A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat Med (2011) 3.60
Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS One (2011) 3.57
Drivers of inequality in Millennium Development Goal progress: a statistical analysis. PLoS Med (2010) 3.30
HIV and tuberculosis: a deadly human syndemic. Clin Microbiol Rev (2011) 3.28
Progression to active tuberculosis, but not transmission, varies by Mycobacterium tuberculosis lineage in The Gambia. J Infect Dis (2008) 3.15
Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog (2012) 2.87
Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS (2009) 2.86
Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a High HIV prevalence setting. J Acquir Immune Defic Syndr (2009) 2.81
In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice. Nat Med (2007) 2.76
Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. J Infect Dis (2011) 2.72
TB database: an integrated platform for tuberculosis research. Nucleic Acids Res (2008) 2.71
Creating and validating an algorithm to measure AIDS mortality in the adult population using verbal autopsy. PLoS Med (2006) 2.70
Spectrum of clinical disease in a series of 135 hospitalised HIV-infected patients from north India. BMC Infect Dis (2004) 2.64
Tuberculosis and HIV co-infection. PLoS Pathog (2012) 2.57
Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Med (2012) 2.54
Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review. PLoS One (2009) 2.51
Induction of a novel class of diacylglycerol acyltransferases and triacylglycerol accumulation in Mycobacterium tuberculosis as it goes into a dormancy-like state in culture. J Bacteriol (2004) 2.51
The resuscitation-promoting factors of Mycobacterium tuberculosis are required for virulence and resuscitation from dormancy but are collectively dispensable for growth in vitro. Mol Microbiol (2008) 2.44
Prevalence of tuberculosis, HIV and respiratory symptoms in two Zambian communities: implications for tuberculosis control in the era of HIV. PLoS One (2009) 2.42
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis (2009) 2.36
Drug-resistant tuberculosis: a worldwide epidemic poses a new challenge. Dtsch Arztebl Int (2010) 2.36
The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis. Immunol Rev (2008) 2.36
Clinical and laboratory observations of tuberculosis at a Mumbai (India) clinic. Postgrad Med J (2004) 2.36
New measurable indicator for tuberculosis case detection. Emerg Infect Dis (2004) 2.34
Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother (2008) 2.33
Challenges in estimating the total burden of drug-resistant tuberculosis. Am J Respir Crit Care Med (2008) 2.33
Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis (2006) 2.29
Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis. Sci Transl Med (2013) 2.28
Comparison between laparoscopy and noninvasive tests for the diagnosis of tuberculous peritonitis. World J Surg (2011) 2.24
Tuberculosis in poorly controlled type 2 diabetes: altered cytokine expression in peripheral white blood cells. Clin Infect Dis (2008) 2.24
Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. J Exp Med (2008) 2.17
Tuberculosis in HIV programmes in lower-income countries: practices and risk factors. Int J Tuberc Lung Dis (2011) 2.15
Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load. PLoS One (2010) 2.14
A highly conserved transcriptional repressor controls a large regulon involved in lipid degradation in Mycobacterium smegmatis and Mycobacterium tuberculosis. Mol Microbiol (2007) 2.13
Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence. BMC Public Health (2005) 2.09
Diabetes mellitus and tuberculosis in countries with high tuberculosis burdens: individual risks and social determinants. Int J Epidemiol (2011) 2.07
Tuberculosis mortality, drug resistance, and infectiousness in patients with and without HIV infection in Peru. Am J Trop Med Hyg (2006) 2.05
Pulmonary tuberculosis: diagnosis and treatment. BMJ (2006) 2.04
Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples. PLoS One (2010) 2.03
Serological testing versus other strategies for diagnosis of active tuberculosis in India: a cost-effectiveness analysis. PLoS Med (2011) 2.02
Bacterial growth and cell division: a mycobacterial perspective. Microbiol Mol Biol Rev (2008) 2.01
Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proc Natl Acad Sci U S A (2006) 2.00
GSMN-TB: a web-based genome-scale network model of Mycobacterium tuberculosis metabolism. Genome Biol (2007) 1.99
Properties and protective value of the secondary versus primary T helper type 1 response to airborne Mycobacterium tuberculosis infection in mice. J Exp Med (2005) 1.98
Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata. Int J Tuberc Lung Dis (2010) 1.97
The Mycobacterium tuberculosis stress response factor SigH is required for bacterial burden as well as immunopathology in primate lungs. J Infect Dis (2012) 1.96
Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob Agents Chemother (2008) 1.95
Treatment outcome of tuberculosis patients at Gondar University Teaching Hospital, Northwest Ethiopia. A five--year retrospective study. BMC Public Health (2009) 1.95
Diagnostic accuracy of commercial urinary lipoarabinomannan detection in African tuberculosis suspects and patients. Int J Tuberc Lung Dis (2009) 1.92
Sensitivity of direct versus concentrated sputum smear microscopy in HIV-infected patients suspected of having pulmonary tuberculosis. BMC Infect Dis (2009) 1.92
Inhibitors selective for mycobacterial versus human proteasomes. Nature (2009) 1.89
Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice. Eur J Clin Microbiol Infect Dis (2005) 1.87
Risk of tuberculosis among people with diabetes mellitus: an Australian nationwide cohort study. BMJ Open (2012) 1.85
Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001. PLoS One (2007) 1.84
Central nervous system tuberculosis. Afr Health Sci (2011) 1.83
The RD1 virulence locus of Mycobacterium tuberculosis regulates DNA transfer in Mycobacterium smegmatis. Proc Natl Acad Sci U S A (2004) 1.82
Tuberculosis chemotherapy: the influence of bacillary stress and damage response pathways on drug efficacy. Clin Microbiol Rev (2006) 1.82
The Beijing genotype and drug resistant tuberculosis in the Aral Sea region of Central Asia. Respir Res (2005) 1.79
Integration of HIV and TB services results in improved TB treatment outcomes and earlier prioritized ART initiation in a large urban HIV clinic in Uganda. J Acquir Immune Defic Syndr (2012) 1.79
Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it? Int J Tuberc Lung Dis (2011) 1.76
Persistently elevated T cell interferon-gamma responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report. J Occup Med Toxicol (2006) 1.76
Did we reach the 2005 targets for tuberculosis control? Bull World Health Organ (2007) 1.76
Role for matrix metalloproteinase 9 in granuloma formation during pulmonary Mycobacterium tuberculosis infection. Infect Immun (2006) 1.75
Has the DOTS strategy improved case finding or treatment success? An empirical assessment. PLoS One (2008) 1.74
Invasion of the central nervous system by intracellular bacteria. Clin Microbiol Rev (2004) 1.71
Suitability of Xpert MTB/RIF and genotype MTBDRplus for patient selection for a tuberculosis clinical trial. J Clin Microbiol (2011) 1.69
Tuberculosis recurrence and mortality after successful treatment: impact of drug resistance. PLoS Med (2006) 1.69
Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa. Clin Vaccine Immunol (2009) 1.67
Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa. PLoS One (2010) 1.67
Global transcriptional profile of Mycobacterium tuberculosis during THP-1 human macrophage infection. Infect Immun (2007) 1.66
Modeling the dynamic relationship between HIV and the risk of drug-resistant tuberculosis. Sci Transl Med (2012) 1.65
Recent advances in the diagnosis of childhood tuberculosis. Arch Dis Child (2007) 1.65
Prevalence of tuberculous infection and incidence of tuberculosis: a re-assessment of the Styblo rule. Bull World Health Organ (2008) 1.65
Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services. Int J Drug Policy (2007) 1.65
Immunogenicity of eight dormancy regulon-encoded proteins of Mycobacterium tuberculosis in DNA-vaccinated and tuberculosis-infected mice. Infect Immun (2006) 1.63
Convergence of the tuberculosis and diabetes epidemics: renewal of old acquaintances. Clin Infect Dis (2007) 1.63
Co-infection of Mycobacterium tuberculosis and Mycobacterium leprae in human archaeological samples: a possible explanation for the historical decline of leprosy. Proc Biol Sci (2005) 1.60
Vitamin D and host resistance to infection? Putting the cart in front of the horse. Exp Biol Med (Maywood) (2010) 1.59
Impact and cost-effectiveness of culture for diagnosis of tuberculosis in HIV-infected Brazilian adults. PLoS One (2008) 1.59
Application of sensitive and specific molecular methods to uncover global dissemination of the major RDRio Sublineage of the Latin American-Mediterranean Mycobacterium tuberculosis spoligotype family. J Clin Microbiol (2008) 1.59
A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. J Antimicrob Chemother (2008) 1.58
Characterization of Mycobacterium tuberculosis Rv3676 (CRPMt), a cyclic AMP receptor protein-like DNA binding protein. J Bacteriol (2005) 1.57
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet (2008) 36.01
Ebola virus disease in West Africa--the first 9 months of the epidemic and forward projections. N Engl J Med (2014) 28.65
Evidence-based, cost-effective interventions: how many newborn babies can we save? Lancet (2005) 18.87
Estimates of maternal mortality worldwide between 1990 and 2005: an assessment of available data. Lancet (2007) 11.59
Evidence-based interventions for improvement of maternal and child nutrition: what can be done and at what cost? Lancet (2013) 8.46
Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet (2010) 7.07
Integrating HIV prevention and treatment: from slogans to impact. PLoS Med (2005) 6.73
Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis (2002) 6.73
The potential impact of male circumcision on HIV in Sub-Saharan Africa. PLoS Med (2006) 6.53
Tuberculosis. Lancet (2003) 6.39
Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med (2009) 5.93
Sub-Saharan Africa's mothers, newborns, and children: where and why do they die? PLoS Med (2010) 5.54
Global incidence of multidrug-resistant tuberculosis. J Infect Dis (2006) 5.42
Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA (2005) 5.39
The international Ebola emergency. N Engl J Med (2014) 5.35
Can we reverse the HIV/AIDS pandemic with an expanded response? Lancet (2002) 5.21
The impact of migration on HIV-1 transmission in South Africa: a study of migrant and nonmigrant men and their partners. Sex Transm Dis (2003) 5.09
The population dynamics and control of tuberculosis. Science (2010) 5.08
Who infects whom? HIV-1 concordance and discordance among migrant and non-migrant couples in South Africa. AIDS (2003) 4.87
Evaluation of respondent-driven sampling. Epidemiology (2012) 4.75
International standards for tuberculosis care. Lancet Infect Dis (2006) 4.67
Monitoring mosquito net coverage for malaria control in Africa: possession vs. use by children under 5 years. Trop Med Int Health (2003) 4.29
Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence. BMC Public Health (2007) 4.13
Transmission of HIV-1 infection in sub-Saharan Africa and effect of elimination of unsafe injections. Lancet (2004) 4.13
Measurement of trends in childhood malaria mortality in Africa: an assessment of progress toward targets based on verbal autopsy. Lancet Infect Dis (2003) 4.10
HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med (2012) 4.08
Can the world afford to save the lives of 6 million children each year? Lancet (2005) 4.07
Estimates of HIV-1 prevalence from national population-based surveys as a new gold standard. Lancet (2003) 3.85
The HIV-associated tuberculosis epidemic--when will we act? Lancet (2010) 3.82
Reducing the global burden of tuberculosis: the contribution of improved diagnostics. Nature (2006) 3.72
Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet (2002) 3.67
Increasing transparency in partnerships for health--introducing the Green Light Committee. Trop Med Int Health (2002) 3.59
Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS One (2011) 3.57
Neonatal survival: a call for action. Lancet (2005) 3.44
Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med (2012) 3.44
Interventions to address deaths from childhood pneumonia and diarrhoea equitably: what works and at what cost? Lancet (2013) 3.41
Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr (2002) 3.40
Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis (2006) 3.32
Alcohol use as a risk factor for tuberculosis - a systematic review. BMC Public Health (2008) 3.32
Diabetes and the risk of tuberculosis: a neglected threat to public health? Chronic Illn (2007) 3.31
Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med (2004) 3.26
Tuberculosis incidence in prisons: a systematic review. PLoS Med (2010) 2.96
West African Ebola epidemic after one year--slowing but not yet under control. N Engl J Med (2014) 2.96
AIDS among older children and adolescents in Southern Africa: projecting the time course and magnitude of the epidemic. AIDS (2009) 2.92
Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science (2003) 2.83
HIV infection, antiretroviral therapy, and CD4+ cell count distributions in African populations. J Infect Dis (2006) 2.82
Impact of malaria control on childhood anaemia in Africa -- a quantitative review. Trop Med Int Health (2004) 2.80
Malaria attributable to the HIV-1 epidemic, sub-Saharan Africa. Emerg Infect Dis (2005) 2.80
Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci U S A (2009) 2.78
Sub-Saharan Africa's mothers, newborns, and children: how many lives could be saved with targeted health interventions? PLoS Med (2010) 2.77
The global impact of scaling up HIV/AIDS prevention programs in low- and middle-income countries. Science (2006) 2.76
Worldwide incidence of malaria in 2009: estimates, time trends, and a critique of methods. PLoS Med (2011) 2.74
Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science (2002) 2.65
Global burden of disease 2005: call for collaborators. Lancet (2007) 2.64
Is operational research delivering the goods? The journey to success in low-income countries. Lancet Infect Dis (2012) 2.62
Cost effectiveness analysis of strategies for tuberculosis control in developing countries. BMJ (2005) 2.50
Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis (2003) 2.49
Saving newborn lives in Asia and Africa: cost and impact of phased scale-up of interventions within the continuum of care. Health Policy Plan (2008) 2.48
Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. Lancet Infect Dis (2006) 2.48
Tuberculosis control in the era of HIV. Nat Rev Immunol (2005) 2.40
Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050. PLoS One (2012) 2.39
Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis (2002) 2.33
Stillbirths: how can health systems deliver for mothers and babies? Lancet (2011) 2.28
A consistent log-linear relationship between tuberculosis incidence and body mass index. Int J Epidemiol (2009) 2.20
Monitoring the scale-up of antiretroviral therapy programmes: methods to estimate coverage. Bull World Health Organ (2006) 2.20
Ebola virus disease in the Democratic Republic of Congo. N Engl J Med (2014) 2.19
Ebola virus disease among children in West Africa. N Engl J Med (2015) 2.17
Overview of the Lives Saved Tool (LiST). BMC Public Health (2013) 2.13
Tuberculosis epidemics driven by HIV: is prevention better than cure? AIDS (2003) 2.11
Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence. BMC Public Health (2005) 2.09
Mathematical models in the evaluation of health programmes. Lancet (2011) 2.05
Extra-couple HIV transmission in sub-Saharan Africa: a mathematical modelling study of survey data. Lancet (2013) 2.03
Eliminating human tuberculosis in the twenty-first century. J R Soc Interface (2008) 2.00
Estimates of child deaths prevented from malaria prevention scale-up in Africa 2001-2010. Malar J (2012) 2.00
Back to basics in HIV prevention: focus on exposure. BMJ (2003) 1.99
Infectiousness in a cohort of brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission. J Infect Dis (2002) 1.97
Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data. Lancet Infect Dis (2013) 1.96
Spatial analysis of tuberculosis cases in migrants and permanent residents, Beijing, 2000-2006. Emerg Infect Dis (2008) 1.91
LiST as a catalyst in program planning: experiences from Burkina Faso, Ghana and Malawi. Int J Epidemiol (2010) 1.90